GlaxoSmithKline News

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

Not all Human Genome Science shareholders agree with the company position that GlaxoSmithKline's $2.6 billion purchase offer is insufficient.

GSK Announces Start of Phase III Programme for Combination of Dabrafenib and Trametinib in BRAF V600 Mutation-Positive Metastatic Cutaneous Melanoma GlaxoSmithKline plc.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Two experimental skin cancer drugs from GlaxoSmithKline - each designed to block different pathways used by tumour cells - look set to steal a march on Roche's pioneering ... (more)

GlaxoSmithKline AIDS drug abacavir holds a hidden key to understanding allergic reactions that some patients experience from other drugs.

The British company had intended to take its $13-a-share offer direct to investors after Human Genome's board said it was inadequate.

This report provides elemental information and data relating to the clinical trials on Soft Tissue Sarcoma.

The city is the home of healthcare retailer Boots and has strong pharmacy and chemistry departments at the University of Nottingham which recently announced that GlaxoSmithKline was giving 12m for new sustainable chemistry laboratories.

GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc.

It was a case of all hands on deck for the 20 GlaxoSmithKline employees when they repainted Cathja in Isleworth.

GlaxoSmithKline may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc.

Drug Giants Such as AstraZeneca PLC , GlaxoSmithKline , Sanofi Join Forces With Academia on $285 Million Antibiotic Pact GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat ... (more)

GlaxoSmithKline Plc may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.

COPENHAGEN, Denmark, May 24, 2012 -- Genmab A/S announced today a milestone payment of DKK 20 million from GlaxoSmithKline to Genmab in connection with the filing of the New Drug Application to the Japanese Ministry of Health, Labor and Welfare .

GlaxoSmithKline shares move lower Wednesday as the firm modifies the terms of its $2.6 billion tender offer for Human Genome , which require that its quarry redeem or invalidate its poison pill.

Just last month GlaxoSmithKline was in the news for a move to acquire Human Genome Sciences , its partner of up to twenty years for $2.6 billion.

While we usually recommend using single-country funds as satellite holdings given their niche exposure, we think iShares MSCI United Kingdom Index is suitable as a core foreign-equity holding.

MALVERN, Pa., May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. is raising its full year 2012 revenue guidance to a range of $293 to $315 million and is reducing its guidance for net loss to a range of $5 to $10 million.

Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline entered into an agreement Monday to co-promote Testim, Auxilium's testosterone replacement therapy product used in adult males.